Immunocore Holdings Balance Sheet Health
Financial Health criteria checks 6/6
Immunocore Holdings has a total shareholder equity of $377.8M and total debt of $438.7M, which brings its debt-to-equity ratio to 116.1%. Its total assets and total liabilities are $1.1B and $706.8M respectively.
Key information
116.1%
Debt to equity ratio
US$438.70m
Debt
| Interest coverage ratio | n/a |
| Cash | US$901.28m |
| Equity | US$377.83m |
| Total liabilities | US$706.81m |
| Total assets | US$1.08b |
Recent financial health updates
Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?
Oct 24
Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?
May 11Here's Why Immunocore Holdings (NASDAQ:IMCR) Can Manage Its Debt Despite Losing Money
Jan 22Recent updates
Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?
Oct 24Immunocore Holdings plc's (NASDAQ:IMCR) Business And Shares Still Trailing The Industry
Sep 19Immunocore Holdings: KIMMTRAK Success, Diverse Pipeline, And Potential Big Pharma Appeal
Aug 12Is Immunocore Holdings plc (NASDAQ:IMCR) Trading At A 33% Discount?
Jul 24Immunocore Holdings plc's (NASDAQ:IMCR) 28% Dip In Price Shows Sentiment Is Matching Revenues
Jun 16Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?
May 11Immunocore Holdings plc (NASDAQ:IMCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
May 11Are Investors Undervaluing Immunocore Holdings plc (NASDAQ:IMCR) By 25%?
Apr 05Here's Why Immunocore Holdings (NASDAQ:IMCR) Can Manage Its Debt Despite Losing Money
Jan 22Immunocore Holdings: Vulnerable To Profit Taking After Big Rally
Jan 21Revenues Not Telling The Story For Immunocore Holdings plc (NASDAQ:IMCR) After Shares Rise 37%
Dec 18Some Confidence Is Lacking In Immunocore Holdings plc's (NASDAQ:IMCR) P/S
May 08Forecast: Analysts Think Immunocore Holdings plc's (NASDAQ:IMCR) Business Prospects Have Improved Drastically
Nov 16Immunocore: Attractive Commercial-Stage Biopharma
Oct 05Need To Know: Analysts Are Much More Bullish On Immunocore Holdings plc (NASDAQ:IMCR)
Aug 12Immunocore GAAP EPS of -$0.17, revenue of $38.92M
Aug 10Immunocore to raise $140M in private placement financing
Jul 18Financial Position Analysis
Short Term Liabilities: IMCR's short term assets ($1.0B) exceed its short term liabilities ($266.2M).
Long Term Liabilities: IMCR's short term assets ($1.0B) exceed its long term liabilities ($440.6M).
Debt to Equity History and Analysis
Debt Level: IMCR has more cash than its total debt.
Reducing Debt: IMCR's debt to equity ratio has reduced from 197.8% to 116.1% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable IMCR has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: IMCR is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 36.1% per year.